Want to see GPCR full AI Analyst Report?
Top Page
Structure Therapeutics, Inc. Sponsored ADR
(NASDAQ:GPCR)
Select Model
Select Model
Rating:57Neutral
Price Target:
$54.00
▲(8.17% Upside)
Action:Reiterated
Date:08/07/26
The score is driven primarily by mixed financial performance (strong balance sheet but significant, ongoing pre-revenue losses and cash burn). Technicals add support with a positive trend and momentum signals. Valuation is pressured by negative earnings and no dividend, while corporate events are modestly positive due to program progress and improved financing flexibility.
Positive Factors
Balance sheet strength
Very low debt-to-equity (~0.4%) and sizable equity provide durable financial flexibility, lowering refinancing risk and supporting multi-year R&D funding. This cushion enables the company to advance late-stage programs without immediate pressure to cut development spending.
Negative Factors
High cash burn
Sustained and growing negative free cash flow (~-$210M TTM) means the business consumes significant capital to fund R&D. Long-term reliance on external financing raises execution risk and can constrain strategic optionality if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low debt-to-equity (~0.4%) and sizable equity provide durable financial flexibility, lowering refinancing risk and supporting multi-year R&D funding. This cushion enables the company to advance late-stage programs without immediate pressure to cut development spending.
Read all positive factors
Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.56B
Dividend YieldN/A
Average Volume (3M)749.96K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS Growth1.47%
CountryUS
Employees233
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.03
Shares Outstanding71,309,860
10 Day Avg. Volume595,420
30 Day Avg. Volume749,963
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$108.62Price Target Upside117.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.63
Revenue Forecast (FY)$38.46M
Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model
Company Description
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment opt...
How the Company Makes Money
null...
Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.22M | -3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -212.44M | -136.79M | -121.22M | -75.70M | -51.03M | -37.62M |
| Net Income | -215.06M | -141.20M | -122.53M | -89.62M | -51.32M | -40.01M |
Balance Sheet | ||||||
| Total Assets | 1.43B | 1.58B | 903.33M | 482.02M | 97.84M | 111.16M |
| Cash, Cash Equivalents and Short-Term Investments | 1.34B | 1.45B | 883.52M | 467.32M | 90.84M | 107.31M |
| Total Debt | 6.23M | 6.49M | 3.86M | 5.45M | 260.00K | 621.00K |
| Total Liabilities | 71.01M | 67.54M | 38.49M | 29.05M | 212.99M | 175.89M |
| Stockholders Equity | 1.35B | 1.52B | 864.84M | 452.97M | -115.14M | -64.73M |
Cash Flow | ||||||
| Free Cash Flow | -224.46M | -225.81M | -117.93M | -81.66M | -46.27M | -33.37M |
| Operating Cash Flow | -220.25M | -222.20M | -116.64M | -79.49M | -46.12M | -32.16M |
| Investing Cash Flow | -417.11M | 89.80M | -358.91M | -268.34M | -62.11M | 17.86M |
| Financing Cash Flow | 761.53M | 762.52M | 515.26M | 451.53M | 29.01M | 103.25M |
Structure Therapeutics, Inc. Sponsored ADR Technical Analysis
Negative
49.92
Price Trends
50.45
Negative
46.87
Positive
53.94
Negative
Market Momentum
0.12
Positive
44.75
Neutral
22.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Negative. The current price of 49.92 is below the 20-day moving average (MA) of 51.51, below the 50-day MA of 50.45, and below the 200-day MA of 53.94, indicating a bearish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 44.75 is Neutral, neither overbought nor oversold. The STOCH value of 22.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GPCR.
Structure Therapeutics, Inc. Sponsored ADR Risk Analysis
Structure Therapeutics, Inc. Sponsored ADR disclosed 102 risk factors in its most recent earnings report. Structure Therapeutics, Inc. Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Structure Therapeutics, Inc. Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $3.56B | -16.29 | -16.91% | ― | ― | 1.47% | |
56 Neutral | $2.16B | -9.85 | -59.36% | ― | -86.20% | -476.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.78B | -7.97 | -372.94% | ― | 222.65% | 35.43% | |
48 Neutral | $1.96B | -14.51 | -72.07% | ― | -69.78% | -106.07% |
* Healthcare Sector Average
GPCR
Structure Therapeutics, Inc. Sponsored ADR
49.22
30.08
157.16%
SNDX
Syndax Pharmaceuticals
20.16
3.84
23.53%
ZYME
Zymeworks
29.01
14.17
95.49%
STOK
Stoke Therapeutics
32.59
12.82
64.85%
Structure Therapeutics, Inc. Sponsored ADR Corporate Events
Executive/Board ChangesShareholder Meetings
Shareholders Approve Directors, Auditors at 2026 Meeting
Positive
Jun 18, 2026
On June 17, 2026, Structure Therapeutics, Inc. held its 2026 Annual General Meeting of Shareholders, with 213,213,565 ordinary shares eligible to vote as of the April 20, 2026 record date. Shareholders elected Ted W. Love, M.D., Raymond Stevens, P...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program
Positive
May 7, 2026
On May 7, 2026, Structure Therapeutics amended and restated its at-the-market sales agreement with Leerink Partners and Cantor Fitzgerald, removing the cap on American Depositary Shares that can be issued and filing a prospectus supplement to lift...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.